Search results
Added:
7 months ago
ESC Congress 2025 - Vericiguat did not reduce the risk of cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, fewer cardiovascular deaths and all-cause deaths were observed.Host, Dr Harriette Van Spall (McMaster University, CA) is joined on-site at ESC Congress 2025 in Madrid by Dr Faiez Zannad (University of Lorraine, FR) to discuss pivotal results from…
View more
Added:
1 year ago
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating…
View more
Added:
1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,…
View more
Added:
10 months ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an…
View more
Added:
1 year ago
HFA 2024 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss insights from the STEP-HFpEF programme.STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the…
View more
Added:
1 year ago
HFA 24 - Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE) joins us in this succinct interview to outline the findings of the RELIEVE-HF trial (NCT03499236).RELIEVE-HF was designed to evaluate the safety and effectiveness of the V-Wave inter-atrial shunt system to reduce lung congestion in patients with advanced heart failure. 605 participants with New York Heart Association (NYHA)…
View more
Added:
1 year ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the…
View more
Added:
1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR…
View more
Added:
1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Dr Patricia Campbell and Prof Paul Kalra share their expert perspectives on the use of IV iron in clinical practice.
View more